Table 11.
The New Drug Application of PD-1 Antibody in China.
| Acceptance Number | Drug | Date | Company | Progress |
|---|---|---|---|---|
| JXSL1600007 | Nivolumab | 17 February 2016 | Bristol-Myers Squibb | In Assessing |
| JXSL1500068 | 7 December 2015 | |||
| JXSL1300032 | 20 May 2013 | In Clinic | ||
| JXSL1600009 | Pembrolizumab | 29 February 2016 | Merck | In Assessing |
| JXSL1600005 | 16 February 2016 | |||
| JXSL1500074 | 31 December 2015 | |||
| JXSL1500058 | 30 September 2015 | |||
| JXSL1500040 | 28 July 2015 | |||
| JXSL1500020 | 25 May 2015 | |||
| CXSL1400138 | JS001-PD-1 | 21 January 2015 | ShangHai JunShi | In Clinic |
| CXSL1400153 | SHR-1210 | 19 January 2015 | ShangHai HengRui | |
| CXSL1500096 | BGB-317 | 11 December 2015 | BeiGene | In Assessing |
| CXSL1600016 | Genor PD-1 Antibody | 7 April 2016 | Genorbio |